Achilles Therapeutics Plc Stock Today
| ACHL Stock | USD 1.05 0.01 0.96% |
Performance12 of 100
| Odds Of DistressLess than 37
|
Achilles Therapeutics is selling for 1.05 as of the 10th of December 2024. This is a 0.96% increase since the beginning of the trading day. The stock's lowest day price was 1.02. Achilles Therapeutics has about a 37 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 11th of September 2024 and ending today, the 10th of December 2024. Click here to learn more.
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States.. The company has 41.09 M outstanding shares of which 215.69 K shares are presently shorted by private and institutional investors with about 1.69 trading days to cover. More on Achilles Therapeutics PLC
Moving against Achilles Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Achilles Stock Highlights
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Achilles Therapeutics PLC (ACHL) is traded on NASDAQ Exchange in USA. It is located in 245 Hammersmith Road, London, United Kingdom, W6 8PW and employs 204 people. Achilles Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 44.85 M. Achilles Therapeutics PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 41.09 M outstanding shares of which 215.69 K shares are presently shorted by private and institutional investors with about 1.69 trading days to cover.
Achilles Therapeutics PLC currently holds about 201.6 M in cash with (48.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Achilles Therapeutics Probability Of Bankruptcy
Ownership AllocationAchilles Therapeutics holds a total of 41.09 Million outstanding shares. Over half of Achilles Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Achilles Ownership Details
Achilles Therapeutics PLC Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Achilles Therapeutics market risk premium is the additional return an investor will receive from holding Achilles Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1233 | |||
| Jensen Alpha | 0.534 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.2494 |
Achilles Stock Against Markets
Achilles Therapeutics Corporate Management
| Sergio Quezada | Founder Officer | Profile | |
| Daniel Hood | General Secretary | Profile | |
| Tariq Ahmed | Executive People | Profile | |
| James Taylor | Chief Officer | Profile | |
| Julia Wilson | Head Communications | Profile | |
| Lee Stern | Vice Communications | Profile | |
| FMEDSCI MD | Founder | Profile |
Already Invested in Achilles Therapeutics PLC?
The danger of trading Achilles Therapeutics PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Achilles Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Achilles Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Achilles Therapeutics PLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.